[Code of Federal Regulations]
[Title 21, Volume 4]
[Revised as of April 1, 2007]
From the U.S. Government Printing Office via GPO Access
[CITE: 21CFR201.56]
[Page 21-23]
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN
SERVICES (CONTINUED)
PART 201 LABELING--Table of Contents
Subpart B Labeling Requirements for Prescription Drugs and/or Insulin
Sec. 201.56 Requirements on content and format of labeling for human
prescription drug and biological products.
(a) General requirements. Prescription drug labeling described in
Sec. 201.100(d) must meet the following general requirements:
(1) The labeling must contain a summary of the essential scientific
information needed for the safe and effective use of the drug.
(2) The labeling must be informative and accurate and neither
promotional in tone nor false or misleading in any particular. In
accordance with Sec. Sec. 314.70 and 601.12 of this chapter, the
labeling must be updated when new information becomes available that
causes the labeling to become inaccurate, false, or misleading.
(3) The labeling must be based whenever possible on data derived
from human experience. No implied claims or suggestions of drug use may
be made if there is inadequate evidence of safety or a lack of
substantial evidence of effectiveness. Conclusions based on animal data
but necessary for safe and effective use of the drug in humans must be
identified as such and included with human data in the appropriate
section of the labeling.
(b) Categories of prescription drugs subject to the labeling content
and format requirements in Sec. Sec. 201.56(d) and 201.57. (1) The
following categories of prescription drug products are subject to the
labeling requirements in paragraph (d) of this section and Sec. 201.57
in accordance with the implementation schedule in paragraph (c) of this
section:
(i) Prescription drug products for which a new drug application
(NDA), biologics license application (BLA), or efficacy supplement was
approved by the Food and Drug Administration (FDA) between June 30, 2001
and June 30, 2006;
(ii) Prescription drug products for which an NDA, BLA, or efficacy
supplement is pending on June 30, 2006; or
(iii) Prescription drug products for which an NDA, BLA, or efficacy
supplement is submitted anytime on or after June 30, 2006.
(2) Prescription drug products not described in paragraph (b)(1) of
this section are subject to the labeling requirements in paragraph (e)
of this section and Sec. 201.80.
(c) Schedule for implementing the labeling content and format
requirements in
[[Page 22]]
Sec. Sec. 201.56(d) and 201.57. For products described in paragraph
(b)(1) of this section, labeling conforming to the requirements in
paragraph (d) of this section and Sec. 201.57 must be submitted
according to the following schedule:
(1) For products for which an NDA, BLA, or efficacy supplement is
submitted for approval on or after June 30, 2006, proposed conforming
labeling must be submitted as part of the application.
(2) For products for which an NDA, BLA, or efficacy supplement is
pending on June 30, 2006, or that has been approved any time from June
30, 2005, up to and including June 30, 2006, a supplement with proposed
conforming labeling must be submitted no later than June 30, 2009.
(3) For products for which an NDA, BLA, or efficacy supplement has
been approved anytime from June 30, 2004, up to and including June 29,
2005, a supplement with proposed conforming labeling must be submitted
no later than June 30, 2010.
(4) For products for which an NDA, BLA, or efficacy supplement has
been approved anytime from June 30, 2003, up to and including June 29,
2004, a supplement with proposed conforming labeling must be submitted
no later than June 30, 2011.
(5) For products for which an NDA, BLA, or efficacy supplement has
been approved anytime from June 30, 2002, up to and including June 29,
2003, a supplement with proposed conforming labeling must be submitted
no later than June 30, 2012.
(6) For products for which an NDA, BLA, or efficacy supplement has
been approved anytime from June 30, 2001, up to and including June 29,
2002, a supplement with proposed conforming labeling must be submitted
no later than June 30, 2013.
(d) Labeling requirements for new and more recently approved
prescription drug products. This paragraph applies only to prescription
drug products described in paragraph (b)(1) of this section and must be
implemented according to the schedule specified in paragraph (c) of this
section.
(1) Prescription drug labeling described in Sec. 201.100(d) must
contain the specific information required under Sec. 201.57(a), (b),
and (c) under the following headings and subheadings and in the
following order:
Highlights of Prescribing Information
Product Names, Other Required Information
Boxed Warning
Recent Major Changes
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Full Prescribing Information: Contents
Full Prescribing Information
Boxed Warning
1 Indications and Usage
2 Dosage and Administration
3 Dosage Forms and Strengths
4 Contraindications
5 Warnings and Precautions
6 Adverse Reactions
7 Drug Interactions
8 Use in Specific Populations
8.1 Pregnancy
8.2 Labor and delivery
8.3 Nursing mothers
8.4 Pediatric use
8.5 Geriatric use
9 Drug Abuse and Dependence
9.1 Controlled substance
9.2 Abuse
9.3 Dependence
10 Overdosage
11 Description
12 Clinical Pharmacology
12.1 Mechanism of action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 Nonclinical Toxicology
13.1 Carcinogenesis, mutagenesis, impairment of fertility
13.2 Animal toxicology and/or pharmacology
14 Clinical Studies
15 References
16 How Supplied/Storage and Handling
17 Patient Counseling Information
(2) Additional nonstandard subheadings that are used to enhance
labeling organization, presentation, or ease of use (e.g., for
individual warnings or precautions, or for each drug interaction) must
be assigned a decimal number that corresponds to their
[[Page 23]]
placement in labeling. The decimal numbers must be consistent with the
standardized identifying numbers listed in paragraph (d)(1) of this
section (e.g., subheadings added to the ``Warnings and Precautions''
section must be numbered 5.1, 5.2, and so on).
(3) Any reference in Highlights to information appearing in the full
prescribing information must be accompanied by the identifying number
(in parentheses) corresponding to the location of the information in the
full prescribing information.
(4) Omit clearly inapplicable sections, subsections, or specific
information. If sections or subsections required under paragraph (d)(1)
of this section are omitted from the full prescribing information, the
heading ``Full Prescribing Information: Contents'' must be followed by
an asterisk and the following statement must appear at the end of
Contents: ``* Sections or subsections omitted from the full prescribing
information are not listed.''
(5) Any risk information that is required under Sec.
201.57(c)(9)(iv) is considered ``appropriate pediatric
contraindications, warnings, or precautions'' within the meaning of
section 505A(l)(2) of the Federal Food, Drug, and Cosmetic Act (the act)
(21 U.S.C. 355A(l)(2)), whether such information appears in the
``Contraindications,'' ``Warnings and Precautions,'' or ``Use in
Specific Populations'' section of labeling.
(e) Labeling requirements for older prescription drug products. This
paragraph applies only to approved prescription drug products not
described in paragraph (b)(1) of this section.
(1) Prescription drug labeling described in Sec. 201.100(d) must
contain the specific information required under Sec. 201.80 under the
following section headings and in the following order:
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Abuse and Dependence
Overdosage
Dosage and Administration
How Supplied
(2) The labeling may contain the following additional section
headings if appropriate and if in compliance with Sec. 201.80(l) and
(m):
Animal Pharmacology and/or Animal Toxicology
Clinical Studies
References
(3) Omit clearly inapplicable sections, subsections, or specific
information.
(4) The labeling may contain a ``Product Title'' section preceding
the ``Description'' section and containing only the information required
by Sec. 201.80(a)(1)(i), (a)(1)(ii), (a)(1)(iii), and (a)(1)(iv) and
Sec. 201.100(e). The information required by Sec. 201.80(a)(1)(i)
through (a)(1)(iv) must appear in the ``Description'' section of the
labeling, whether or not it also appears in a ``Product Title.''
(5) The labeling must contain the date of the most recent revision
of the labeling, identified as such, placed prominently immediately
after the last section of the labeling.
(6) The requirement in Sec. 201.80(f)(2) to reprint any FDA-
approved patient labeling at the end of prescription drug labeling or
accompany the prescription drug labeling must be implemented no later
than June 30, 2007.
[71 FR 3986, Jan. 24, 2006]
Back to Top
© 2007 Betterchem Corp.
|
